 |
|
|
|
|
|
Vitaros®
Vitaros® (topical alprostadil and NexACT® for the treatment of Erectile Dysfunction: approved in Europe and Canada)
According to the Canadian approval, Vitaros® offers rapid onset with significant efficacy, tolerability and a favorable safety profile, including patients with compromised cardiovascular system such as diabetics or patients not responding to Viagra® after a prostatectomy.
Phosphodiesterase inhibitors are effective in Erectile Dysfunction but can cause serious cardiovascular safety issues as well as significant side effects such as headache, muscle ache and impaired hearing and vision. Availability of a safer and effective treatment would address an unmet medical need. Apricus Bio's alprostadil topical cream Vitaros® in combination with the NexACT® proprietary novel excipient (DDAIP.HCL) has been designed to provide a rapid onset with significant efficacy, tolerability and a favorable safety profile.
Vitaros® has been studied in over 3,300 patients including difficult to treat populations (diabetes, cardiac issues, sildenafil failures, prostatectomies, patients on nitrates and alpha blockers.) Vitaros® demonstrates clinical efficacy and an excellent safety profile versus currently approved oral medication. For more information please go to: http://www.vitaros.ca/
|
|
|
|
| |
|
|
|
Market approval in Europe